Danish Elder Lymphoma Patient Hematopoietic Investigation

Launched by RIGSHOSPITALET, DENMARK · Feb 8, 2022

Keywords

ClinConnect Summary

This clinical trial, called the Danish Elder Lymphoma Patient Hematopoietic Investigation, aims to better understand how chemotherapy affects older patients with lymphoma, a type of cancer. Researchers want to find out how common DNA mutations are in the blood of patients aged 60 and over who have received chemotherapy. These mutations can lead to more side effects and may affect how well patients feel during and after treatment. By studying blood samples and collecting information from patients about their experiences, the team hopes to uncover important insights that could improve treatment outcomes and quality of life for older lymphoma patients.

To be eligible for the study, participants must be at least 60 years old and have been diagnosed with a specific type of lymphoma known as B-cell Non-Hodgkin lymphoma, for which they need further treatment. The trial is currently recruiting participants, and the researchers expect to include around 300 patients over the next four years. Those who join the study can expect to provide blood samples and answer questions about their health and experiences with treatment. This research is crucial for finding better ways to support the health and wellbeing of older individuals facing lymphoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of r/r B-cell Non-Hodgkin lymphoma
• • In need of systemic treatment with second (2.) or higher line of active therapy for lymphoma
• • 60 years of age or older (no age maximum)
• Exclusion Criteria:
• • Unable to give written consent
• • Non-Danish citizens